替戈拉赞与质子泵抑制剂用于一线根除治疗的比较：一项系统评价与荟萃分析
Comparison of tegoprazan and proton pump inhibitors for first-line eradication: a systematic review with meta-analysis.
作者信息
Cho Jun-Hyung, Jin So-Young, Park Suyeon
机构信息
Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea.
Department of Pathology, Soonchunhyang University Hospital, Seoul, Korea.
出版信息
Expert Rev Anti Infect Ther. 2025 Feb-Apr;23(2-4):227-233. doi: 10.1080/14787210.2025.2459722. Epub 2025 Jan 29.
BACKGROUND
Tegoprazan (TPZ), a potassium-competitive acid blocker with potent gastric acid-suppressing activity, may be a potential agent for treating infection. The study aimed to evaluate the efficacy of TPZ-based therapy for eradication compared with proton pump inhibitor (PPI)-based therapy.
RESEARCH DESIGN AND METHODS
A comprehensive literature search was conducted up to August 2024 using PubMed, Embase, and the Cochrane Library to investigate the beneficial effects of TPZ-based therapy for eradication. Studies that evaluated the eradication rates between the TPZ- and PPI-based therapies were included. The authors conducted a meta-analysis to calculate the eradication rate and pooled risk ratio (RR) with a 95% confidence interval.
RESULTS
Seven studies involving 3200 patients were included. eradication rates did not differ significantly between the TPZ- and PPI-based therapies based on the intention-to-treat (77.3% vs. 76.4%, = 0.68; pooled RR = 1.01 [0.97-1.05]) and per-protocol (84.3% vs. 84.2%, = 0.69; pooled RR = 1.01 [0.98-1.04]) analyses. Additionally, no significant difference was observed in the adverse drug events between TPZ- and PPI-based therapies (27.2% vs. 30.8%, = 0.26; pooled RR = 0.91 [0.76-1.08]).
CONCLUSIONS
eradication and adverse drug event rates with TPZ- and PPI-based treatments were similar.
背景
替戈拉赞（TPZ）是一种具有强大胃酸抑制活性的钾竞争性酸阻滞剂，可能是治疗感染的潜在药物。本研究旨在评估与基于质子泵抑制剂（PPI）的疗法相比，基于TPZ的疗法根除[某种感染]的疗效。
研究设计与方法
截至2024年8月，使用PubMed、Embase和Cochrane图书馆进行了全面的文献检索，以研究基于TPZ的疗法根除[某种感染]的有益效果。纳入评估基于TPZ的疗法和基于PPI的疗法之间根除率的研究。作者进行了荟萃分析，以计算根除率和合并风险比（RR）及95%置信区间。
结果
纳入了7项涉及3200例患者的研究。基于意向性分析（77.3%对76.4%，P = 0.68；合并RR = 1.01 [0.97 - 1.05]）和符合方案分析（84.3%对84.2%，P = 0.69；合并RR = 1.01 [0.98 - 1.04]），基于TPZ的疗法和基于PPI的疗法之间的根除率无显著差异。此外，基于TPZ的疗法和基于PPI的疗法之间在药物不良事件方面未观察到显著差异（27.2%对30.8%，P = 0.26；合并RR = 0.91 [0.76 - 1.08]）。
结论
基于TPZ的治疗和基于PPI的治疗在根除[某种感染]及药物不良事件发生率方面相似。
Zotero 插件